Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hemispherx BioPharma, Inc : Hemispherx Publishes Data on the Bioactivity of Ampligen® in Chronic Fatigue Syndrome (“CFS”) Peer-Reviewed Data in Two Publications Supports the Pending NDA Application

03/19/2012 | 08:21am EDT

Hemispherx Publishes Data on the Bioactivity of Ampligen® in Chronic Fatigue Syndrome ("CFS")

Peer-Reviewed Data in Two Publications Supports the Pending NDA Application

Philadelphia, PA, Monday, March 19, 2012: Hemispherx Biopharma, Inc. (NYSE Amex: HEB) (the "Company" or "Hemispherx") announced the publication of a peer-reviewed article providing the results from the AMP-516 Phase III Clinical Trial of Ampligen® [rintatolimod, Poly (I) • (C12,U)], an experimental therapeutic, in the high impact, online journal, PLoS ONE. The report is entitled "A Double-Blind, Placebo-Controlled, Randomized, Clinical Trial of the TLR-3 Agonist Rintatolimod in Severe Cases of Chronic Fatigue Syndrome". Recently, researchers from the Centers for Disease Control and Prevention ("CDC") and Harvard School of Public Health published new data showing the profound economic impact of CFS on increasing healthcare costs of $452 million and decreasing CFS patient productivity by $1.2 billion in Georgia, a state with approximately 5.5 million people age 18-59 (Cost Effectiveness and Resource Allocation, 9:1, 2011).

In the current PLoS One publication, a Phase III, FDA authorized study in CFS evaluated the safety and therapeutic effectiveness of Ampligen®, an experimental therapeutic, in 234 subjects with debilitating CFS at 12 clinical sites in the United States. The Ampligen® treatment was generally well-tolerated. The article can be found at http://dx.plos.org/10.1371/journal.pone.0031334.

The primary endpoint, exercise tolerance, improved an average of 21% in subjects receiving Ampligen® compared to placebo and the proportions of patients with exercise improvements of at least 25% and 50% were 1.7 and 1.9-fold greater for the Ampligen® group versus placebo (p<0.05). an="" ad="" hoc="" continuous="" responder="" analysis="" of="" exercise="" improvement="" between="" 25%="" and="" 50%="" at="" 5%="" increments="" demonstrated="" a="" significantly="" greater="" response="" for="" patients="" receiving="" ampligen®="" compared="" to="" placebo.="">

The Ampligen® cohort also reduced dependence on medications used to reduce symptoms of CFS compared to the placebo group (p<0.05), adding="" additional="" insight="" to="" the="" recent="" cdc/harvard="" study="" which="" emphasizes="" the="" overwhelming="" economic="" burden="" of="" medical="" care="" for="" cfs="" sufferers.="">

In 2010, Hemispherx published new data showing that a greater proportion of placebo patients in this Phase III trial were found to have a significant prolongation of the EKG QT interval compared to patients who received Ampligen®. Prolongation of the QT interval, which is a risk factor for sudden cardiac death and arrhythmias, was associated with continued use of certain drugs by CFS sufferers known to prolong the QT interval (Journal of Applied Research, 10:3, 2010). CFS patients are considered to be at increased risk for catastrophic cardiac events despite their relatively young age and the preponderance of women (approximately 2-3 women for each man) who suffer from this chronically debilitating disease.

On January 11, 2012, Hemispherx announced that the FDA had granted an extension of its pending New Drug Application ("NDA") for potential treatment of CFS. The Company is currently conducting "open-label" treatment protocol in the U.S. and evaluating new diagnostic modalities to provide additional insights into the CFS disorder.

The FDA originally concluded (Complete Response Letter received 11/25/09) that this Phase III study was inadequate to support approval of the NDA. However, the new analyses and other insights in the PLoS One report supplement the original study findings. The Company believes that continued efforts to understand existing data and to advance the development of new data and information, will ultimately support a re-filing of the NDA.

About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen® and Alferon® LDO. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.

Information contained in this news release, other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen® and Alferon® LDO) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. The planning, completion, results or submission of clinical trials do not imply that any study product will ever be approved commercially for the studied or other treatment indications.

distributed by

This press release was issued by Hemispherx Biopharma Inc. and was initially posted at http://www.hemispherx.net/content/investor/default.asp?goto=729 . It was distributed, unedited and unaltered, by noodls on 2012-03-19 14:17:19 PM. The issuer is solely responsible for the accuracy of the information contained therein.

© Publicnow 2012
09/21AIM IMMUNOTECH INC. : Change in Directors or Principal Officers (form 8-K)
09/21AIM Immunotech Inc. Announces Retirement of Ellen Lintal as Chief Financial Officer, Ef..
09/21AIM IMMUNOTECH : FDA Meeting Request for Ampligen Study Transferred to Neurology Division;..
09/21AIM IMMUNOTECH : Announces Positive Progress on Requested FDA Meeting for Proposed Amplige..
09/21AIM Immunotech Announces Positive Progress on Requested FDA Meeting for Proposed Amplig..
09/20AIM IMMUNOTECH : Provides an Update on Its Pending Phase 2a Human Challenge Trial Using it..
09/20AIM ImmunoTech Inc. Provides Status Update on its Pending Phase 2A Human Challenge Tria..
09/17AIM IMMUNOTECH : Company Presentation - September 2021
09/17AIM IMMUNOTECH INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
09/08AIM IMMUNOTECH : Files Pre-Investigational New-Drug Application for Therapy to Treat Post ..
More news
Managers and Directors
Thomas Kenwood Equels Executive Vice Chairman, President & CEO
Ellen M. Lintal Chief Financial Officer
William M. Mitchell Chairman
David R. Strayer Chief Scientific & Medical Officer
Peter W. Rodino COO, Secretary & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE333.01%85 255
WUXI APPTEC CO., LTD.34.39%68 592